Project Grant K01OD036469
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $126K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $672,844 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by Northwestern University to target the MHC I chain-related molecule (MIC) to augment adoptive natural killer (NK) cell therapy using the canine soft tissue sarcoma model. The research aims to better understand and optimize combination therapy approaches involving anti-MIC antibodies that can modulate the tumor microenvironment to reinvigorate CD8...
- This $131,910 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Virginia Polytechnic Institute & State University (Virginia Tech) seeks to further the development of histotripsy, a non-thermal ablation technique, for the treatment of osteosarcoma (OS) in dogs. The project aims to: 1) investigate the treatment parameters and strategies needed for complete ablation of ex vivo canine OS tumors, and 2) test these strategies in pilot clinical...
- Oregon State University will receive $500,000 from the National Science Foundation under the Technology, Innovation, and Partnerships program to develop cancer therapeutics for dogs. Specifically, the university will construct and test prototype dual epitope-binding therapeutic antibodies targeting the canine PD-1 protein for the treatment of canine cancers. Researchers will design various single domain antibody configurations and select an optimal construct using recombinant DNA methods and...
- This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to improve mucosal melanoma therapy by harnessing the immunogenicity of the R3LCMV virus. The $667,553 award to Northwestern University, spanning 2025-2029, has two key objectives: Determine whether neoadjuvant R3LCMV treatment improves disease-free survival in dogs with naturally occurring mucosal melanoma through a placebo-controlled veterinary...
- This federal Project Grant award of $635,033, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program), supports research to understand the genetic basis of a newly recognized cancer-prone syndrome caused by long telomere length. The award was granted to The Johns Hopkins University, a leading federal research contractor, to conduct comprehensive investigations into this genetic mechanism driving cancer development, which is distinct from tumor...
- This Project Grant award of $138,846 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports a research project to develop "wild-like" laboratory mouse models that better mimic the adult human immune system. The goal is to produce mice with a more mature immune profile, in contrast to the immature immune system typically seen in standard laboratory mice, to enable more accurate translation of cancer and immunotherapy research findings...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $419,080.00 to Virginia Polytechnic Institute & State University (Virginia Tech) to evaluate a combination therapy approach using histotripsy tumor ablation and the immunostimulant n-dihydrogalactochitosan (GC) for treating osteosarcoma. The award will fund a comparative oncology study that incorporates murine preclinical models and pet dogs with spontaneous appendicular...
- The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $445,000 project grant to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant, awarded on January 22, 2025, supports DFCI's research on the molecular mechanisms of DNA double-strand break repair by homologous recombination, a critical process for cell survival and cancer prevention. The project aims to define the complex...
- The National Cancer Institute (NCI) awarded Lifengine Animal Health Laboratories Incorporated a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The award period runs from August 4, 2025 to July 31, 2026. The grant funds the development of chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion by overexpressing the C-MYB transcription factor. This research aims to improve the therapeutic efficacy and duration of...
- This federal Project Grant award of $2,015,762, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), will support the "Test of Rapamycin in Aging Dogs (TRIAD)" clinical trial. The trial aims to determine whether once-weekly rapamycin treatment can increase lifespan and maintain health in 580 companion dogs over a 3-year period. Key objectives include assessing the impact of rapamycin on lifespan, age-related diseases, physical function, neurological function, and...